Drug makers and health insurers fell slightly as traders hedged their bets on the outlook for deal activity and drug developments. Johnson & Johnson and Bayer AG announced plans Friday to launch clinical trials of the anticoagulant Xarelto against three new diseases in an ambitious bid to widen the market for a drug poised to exceed $1 billion in sales this year.

-Rob Curran, rob.curran@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Johnson and Johnson Charts.